PRQR Financials | Key Metrics & Investor Analysis

The financial statements for PRQR (PRQR) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.

See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.

Financial Statements

Related peers

Compare More →
EDIT
Editas Medicine, Inc.
$3.37
-0.59%
ZURA
Zura Bio Limited
$5.69
-0.52%
R
Ryder System, Inc.
$212.05
-3.54%
TRDA
Entrada Therapeutics, Inc.
$13.99
-0.29%
ARCT
Arcturus Therapeutics Holdings Inc.
$8.62
-0.69%
CAPR
Capricor Therapeutics, Inc.
$35.04
+0.92%

Frequently Asked Questions

What are PRQR's latest financial results?

Review PRQR's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.

How has PRQR's revenue and net income changed over time?

Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.

What is PRQR's cash flow situation and liquidity?

Cash flow statements reveal how PRQR generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.

How does PRQR's financial performance compare to industry peers?

Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether PRQR is outperforming or lagging within its sector.

Are PRQR's financial statements showing sustainable profitability?

By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether PRQR's profits are repeatable and supported by strong fundamentals.